Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 3 clinical study titled AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02). The study aims to evaluate the effectiveness of a combination treatment of Sigvotatug Vedotin and pembrolizumab versus pembrolizumab alone in patients with advanced non-small cell lung cancer (NSCLC) with high PD-L1 levels.
The study is testing two interventions: Sigvotatug Vedotin, an MMAE-antibody drug conjugate targeting Integrin Beta-6, and pembrolizumab, an anti-PD-(L)1 drug. The combination is intended to enhance the immune response against cancer cells.
This interventional study is designed with a randomized allocation and a parallel intervention model. It employs single masking, where the outcomes assessor is blinded, and its primary purpose is treatment.
The study began on July 23, 2025, with the last update submitted on August 18, 2025. These dates mark the commencement of participant recruitment and the most recent information update, respectively.
The study’s progress could influence Pfizer’s stock performance and investor sentiment, as successful results may enhance its competitive position in the oncology market. Investors will be keenly watching for updates, given the potential market impact of a new treatment for NSCLC.
The study is currently recruiting, with further details available on the ClinicalTrials portal.